227 related articles for article (PubMed ID: 27247969)
1. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review.
Ginter A; Migliori ME
R I Med J (2013); 2016 Jun; 99(6):26-9. PubMed ID: 27247969
[TBL] [Abstract][Full Text] [Related]
2. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
5. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
7. Anatomic Considerations in Thyroid Eye Disease.
Dutton JJ
Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S7-S12. PubMed ID: 29870437
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
9. IgG4-related orbital disease masquerading as thyroid eye disease, vice versa, or both?
Khandji J; Campbell AA; Callahan AB; Sirinek P; Kazim M
Orbit; 2018 Aug; 37(4):239-242. PubMed ID: 29053038
[TBL] [Abstract][Full Text] [Related]
10. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
11. [Management of Graves' ophthalmopathy].
Schalin-Jäntti C
Duodecim; 2010; 126(20):2431-7. PubMed ID: 21125757
[TBL] [Abstract][Full Text] [Related]
12. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of Graves' ophthalmopathy.
Stiebel-Kalish H; Robenshtok E; Gaton DD
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
[TBL] [Abstract][Full Text] [Related]
14. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment in thyroid eye disease in 2020.
Khong JJ; McNab A
Br J Ophthalmol; 2021 Mar; 105(3):299-305. PubMed ID: 32447327
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
17. Thyroid eye disease: therapy in the active phase.
Bhatti MT; Dutton JJ
J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
[TBL] [Abstract][Full Text] [Related]
18. Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids.
Précausta F; Arsène S; Renoult-Pierre P; Laure B; Crinière L; Pisella PJ
Ann Endocrinol (Paris); 2017 Feb; 78(1):20-26. PubMed ID: 28185649
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies for thyroid eye disease.
Kahaly GJ
Curr Opin Endocrinol Diabetes Obes; 2019 Oct; 26(5):250-255. PubMed ID: 31356255
[TBL] [Abstract][Full Text] [Related]
20. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.
Shams PN; Ma R; Pickles T; Rootman J; Dolman PJ
Am J Ophthalmol; 2014 Jun; 157(6):1299-305. PubMed ID: 24582992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
